Melanoma tumor-infiltrating lymphocytes derived from four distinct anatomic sites obtained from a single patient: Comparison of functional reactivity and melanoma antigen recognition

Journal of Immunotherapy

Volumn 18, Issue 4, 1995, Pages 263-271

  Yannelli, John R ^a   McConnell, Susan ^a   Parker, Linda ^a   Nishimura, Michael ^a   Robbins, Paul ^a   Yang, James ^a   Gamil, Mona El ^a   Kawakami, Yutaka ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cytotoxicity; Immunotherapy; MART 1; Melanoma; TIL

Indexed keywords

LEUKOCYTE ANTIGEN; T LYMPHOCYTE RECEPTOR;

ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CASE REPORT; CYTOTOXICITY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MELANOMA; METASTASIS; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY;

ADRENAL GLAND NEOPLASMS; ANTIGENS, NEOPLASM; AXILLA; CELL DIVISION; CELL LINE; COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOPHENOTYPING; LYMPH NODES; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; NEOPLASM PROTEINS; THORAX;

EID: 0029552391     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199511000-00007     Document Type: Article

References (31)

1. Itoh K, Tilden AB, Balch CM. Interleukin-2 activation of cytotoxic T lymphocytes infiltrating into human metastatic melanomas. Cancer Res 1986;46:3011-17.
2. Muul LM, Spiess PJ, Director EP, Rosenberg SA. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 1987;138:989-95.
3. Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989;142:3714-25.
4. Hom SS, Schwartzentruber DJ, Rosenberg SA, Topalian SL. Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens. J Immunother 1993;13:18-30.
5. Schwartzentruber DJ, Topalian SL, Mancini M, et al. Specific release of granulocyte-macrophage colony stimulating factor, tumor necrosis factor-alpha and IFN-g by human tumor infiltrating lymphocytes after autologous tumor stimulation. J Immunol 1991;146:3674-81.
6. Schwartzentruber DJ, Solomon D, Rosenberg SA, et al. Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion. J Immunother 1992;12:1-12.
7. Horn SS, Rosenberg SA, Topalian SL. Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas: analysis by cytokine secretion. Cancer Immunol Immunother 1993;36:1-8.
8. Kradin RL, Kurnick JT, Lazarus DS, et al. Tumor infiltrating lymphocytes and interleukin-2 in the treatment of advanced cancer. Lancet 1989;1:577-80.
9. Rabinowich H, Cohen R, Bruderman I, et al. Functional analysis of mononuclear cells infiltrating into tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes. Cancer Res 1987;47:173-7.
10. Saito T, Tanaka R, Yoshida S, et al. Immunohistochemical analysis of tumor infiltrating lymphocytes and major histocompatibility antigens in human gliomas and metastatic brain tumors. Surg Neurol 1988;29:435-42.
11. Heo DS, Whiteside TL, Kanbour A, et al. Lymphocytes infiltrating human ovarian tumors. I. Role of leu-19 (NKH1) positive recombinant r-IL2 activated cultures of lymphocytes infiltrating human ovarian tumors. J Immunol 1988;140:4042-9.
12. Belldegrun A, Muul LM, Rosenberg SA. interleukin-2 expanded tumor infiltrating lymphocytes in human renal cell cancer: isolation, characterization and anti-tumor activity. Cancer Res 1988;48:206-14.
13. Yannelli JR, Hyatt C, McConnell S, et al. The growth of tumor infiltrating lymphocytes from human solid cancers: summary of a 4 year experience. Int J Cancer 1995 (in press).
14. Aebersold P, Hyatt C, Johnson S, et al. Lysis of autologous melanoma cells by tumor infiltrating lymphocytes: association with clinical response. J Natl Cancer Inst 1991;83:932-7.
15. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma using autologous tumor infiltrating lymphocytes. J Natl Cancer Inst 1994;86:1159-66.
16. Schwartzentruber DJ, Hom SS, Dadmarz R, et al. In vitro predictors of response in melanoma patients receiving tumor infiltrating lymphocytes and interleukin-2. J Clin Oncol 1994;12:1475-83.
17. Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989;142:3714-25.
18. Van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on human melanoma. Science 1991;254:1643-7.
19. Celis E, Tsai V, Crimi C, et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 1994;91:2105-9.
20. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-19.
21. Coulie PG, Brichard V, Van Pael A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42.
22. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91:6458-62.
23. +melanoma. J Exp Med 1993;178:489-95.
24. Robbins PF, El-Gamil M, Kawakami Y, Stevens EM, Yannelli JR, Rosenberg SA. Recognition of tyrosinase by tumor infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res 1994;54:3124-6.
25. Wang RF, Robbins PF, Kawakami Y, Kang XQ, Rosenberg SA. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 1995;181:799-804.
26. Townsend A, Bodmer H. Antigen recognition by class-I restricted T lymphocytes. Annu Rev Immunol 1989;7:60-82.
27. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of MART-1 human melanoma antigen recognized by the majority of HLA-A2- restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-52.
28. Topalian SL, Solomon D, Avis FP, et al. Immunotherapy of patients with advanced cancer using tumor infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol 1988;6:839-53.
29. Yannelli JR, Hyatt C, Johnson S, Hwu P, Rosenberg SA. Characterization of human tumor cell lines transduced with the cDNA encoding either tumor necrosis factor alpha (TNF-alpha) or interleukin-2 (IL-2). J Immunol Methods 1993;161:77-90.
30. Salter RD, Cresswell P. Impaired assembly and transport of HLA-A and -B antigens in mutant T×B cell hybrid. EMBO J 1986;5:943-8.
31. Shilyansky J, Nishimura MI, Yannelli JR, et al. T-cell receptor usage by melanoma specific clonal and highly oligoclonal tumor infiltrating lymphocyte lines. Proc Natl Acad Sci USA 1994;91:2829-33.